ReviewFrontiers in cellular neuroscience2026
Peripheral biomarkers of neuronal damage in neuropsychiatric systemic lupus erythematosus (NPSLE).
Review in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with heterogeneous clinical presentations, including Neuropsychiatric SLE (NPSLE), which comprises a spectrum of central and peripheral nervous system manifestations attributable to immune-mediated neuronal and glial injury. Currently, diagnosing NPSLE is challenging due to the heterogeneous clinical manifestations and the lack of specific biomarkers. Breakthrough biomarkers are essential for improving diagnostic accuracy, prognostic assessment, and therapeutic monitoring in NPSLE. Serum biomarkers have been thoroughly examined, including inflammatory molecules such as cytokines, chemokines, and autoantibodies; however, these biomarkers are not brain-specific and have also been associated with other clinical domains of SLE. The present review focuses on neuronal and glial damage biomarkers in the context of NPSLE, highlighting their potential utility as diagnostic or prognostic biomarkers, while underscoring the need for further research in this area. Here, we discuss correlations between serum and cerebrospinal fluid (CSF) levels, supporting the use of serum as a minimally invasive surrogate for CNS assessment. Furthermore, findings on serum biomarkers of neurological damage were reviewed to explore their associations with clinical, demographic, and routine laboratory variables, which could provide insights into disease mechanisms. We identified potential biomarkers and highlighted important research gaps that may guide future investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.